Advertisement

Fragile X Syndrome

  • Rebecca Kronk
  • Robyn A. Filipink
Chapter

Abstract

This chapter offers a synopsis of research studies identifying various sleep patterns in children with Fragile X syndrome. New research has begun to recognize sleep problems across the life span in individuals with Fragile X-associated disorders. Epidemiologic and treatment approaches involve recognizing the interaction of biopsychosocial variables which have been conceptualized using the International Classification of Functioning, Disability and Health-Children and Youth Version. There is a need for well-designed double-blind crossover studies investigating the effectiveness of medications and behavioral interventions in treating sleep problems. The immediate and long-term impact of these treatments on family satisfaction and functioning must also be measured and documented.

Keywords

Fragile X syndrome Fragile X-associated disorders FMR1 allele FMRP Sleep International Classification of Functioning Disability Health 

References

  1. 1.
    Chonchaiya W, Schneider A, Hagerman RJ. Fragile X: a family of disorders. Adv Pediatr. 2009;56(1):165–86.PubMedPubMedCentralGoogle Scholar
  2. 2.
    Hessl D, Rivera SM, Reiss AL. The neuroanatomy and neuroendocrinology of fragile X syndrome. Ment Retard Dev Disabil Res Rev. 2004;10(1):17–24.PubMedPubMedCentralGoogle Scholar
  3. 3.
    Coffee B, Keith K, Albizua I, Malone T, Mowrey J, Sherman SL, Warren ST. Incidence of fragile X syndrome by newborn screening for methylated FMR1 DNA. Am J Hum Genet. 2009;85(4):503–14.PubMedPubMedCentralGoogle Scholar
  4. 4.
    Bailey DB, Raspa M, Olmsted M, Holiday DB. Co-occurring conditions associated with FMR1 gene variations: findings from a national parent survey. Am J Med Genet A. 2008;146(16):2060–9.Google Scholar
  5. 5.
    Monaghan KG, Lyon E, Spector EB. ACMG Standards and Guidelines for fragile X testing: a revision to the disease-specific supplements to the standards and guidelines for clinical genetics Laboratories of the American College of medical genetics and genomics. Genet Med. 2013;15(7):575–86.PubMedPubMedCentralGoogle Scholar
  6. 6.
    Dombrowski C, Levesque S, Morel M, Rouillard P, Morgan K, Rousseau F. Premutation and intermediate-size FMR1 alleles in 10 572 males from the general population: loss of an AGG interruption is a late event in the generation of fragile X syndrome alleles. Hum Mol Genet. 2002;11(4):371–8.PubMedPubMedCentralGoogle Scholar
  7. 7.
    Pesso R, Berkenstadt M, Cuckle H, Gak E, Peleg L, Frydman M, Barkai G. Screening for fragile X syndrome in women of reproductive age. Prenat Diagn. 2000;20(8):611–4.PubMedPubMedCentralGoogle Scholar
  8. 8.
    Rousseau F, Rouillard P, Morel M-L, Khandjian EW, Morgan K. Prevalence of carriers of premutation-size alleles of the FMRI gene--and implications for the population genetics of the fragile X syndrome. Am J Hum Genet. 1995;57(5):1006.PubMedPubMedCentralGoogle Scholar
  9. 9.
    Tzeng CC, Tsai LP, Hwu WL, Lin SJ, et al. Prevalence of the FMR1 mutation in Taiwan assessed by large-scale screening of newborn boys and analysis of DXS548-FRAXAC1 haplotype. Am J Med Genet A. 2005;133(1):37–43.Google Scholar
  10. 10.
    Fernandez-Carvajal I, Posadas BL, Pan R, Raske C, Hagerman PJ, Tassone F. Expansion of an FMR1 grey-zone allele to a full mutation in two generations. J Mol Diagn. 2009;11(4):306–10.PubMedPubMedCentralGoogle Scholar
  11. 11.
    Jacquemont S, Hagerman RJ, Leehey MA, Hall DA, et al. Penetrance of the fragile X–associated tremor/ataxia syndrome in a premutation carrier population. JAMA. 2004;291(4):460–9.PubMedPubMedCentralGoogle Scholar
  12. 12.
    Coffey SM, Cook K, Tartaglia N, Tassone F, et al. Expanded clinical phenotype of women with the FMR1 premutation. Am J Med Genet A. 2008;146(8):1009–16.Google Scholar
  13. 13.
    Hagerman RJ, Hall DA, Coffey S, Leehey M, et al. Treatment of fragile X-associated tremor ataxia syndrome (FXTAS) and related neurological problems. Clin Interv Aging. 2008;3(2):251.PubMedPubMedCentralGoogle Scholar
  14. 14.
    Jacquemont S, Hagerman RJ, Leehey M, Grigsby J, et al. Fragile X premutation tremor/ataxia syndrome: molecular, clinical, and neuroimaging correlates. Am J Hum Genet. 2003;72(4):869–78.PubMedPubMedCentralGoogle Scholar
  15. 15.
    Hamlin A, Liu Y, Nguyen DV, Tassone F, Zhang L, Hagerman RJ. Sleep apnea in fragile X premutation carriers with and without FXTAS. Am J Med Genet B Neuropsychiatr Genet. 2011;156(8):923–8.Google Scholar
  16. 16.
    Summers S, Cogswell J, Goodrich J, Mu Y, Nguyen D, Brass S, Hagerman R. Prevalence of restless legs syndrome and sleep quality in carriers of the fragile X premutation. Clin Genet. 2014;86(2):181–4.PubMedPubMedCentralGoogle Scholar
  17. 17.
    Sullivan SD, Welt C, Sherman S. FMR1 and the continuum of primary ovarian insufficiency. Semin Reprod Med. 2011; 29(4):299–307.PubMedPubMedCentralGoogle Scholar
  18. 18.
    Cronister A, Teicher J, Rohlfs EM, Donnenfeld A, Hallam S. Prevalence and instability of fragile X alleles: implications for offering fragile X prenatal diagnosis. Obstet Gynecol. 2008;111(3):596–601.PubMedPubMedCentralGoogle Scholar
  19. 19.
    Seltzer MM, Baker MW, Hong J, Maenner M, Greenberg J, Mandel D. Prevalence of CGG expansions of the FMR1 gene in a US population-based sample. Am J Med Genet B Neuropsychiatr Genet. 2012;159(5):589–97.PubMedCentralGoogle Scholar
  20. 20.
    Tassone F, Iong KP, Tong T-H, Lo J, et al. FMR1 CGG allele size and prevalence ascertained through newborn screening in the United States. Genome Med. 2012;4(12):100.PubMedPubMedCentralGoogle Scholar
  21. 21.
    Nolin SL, Sah S, Glicksman A, Sherman SL, et al. Fragile X AGG analysis provides new risk predictions for 45–69 repeat alleles. Am J Med Genet A. 2013;161(4):771–8.Google Scholar
  22. 22.
    Yrigollen CM, Durbin-Johnson B, Gane L, Nelson DL, Hagerman R, Hagerman PJ, Tassone F. AGG interruptions within the maternal FMR1 gene reduce the risk of offspring with fragile X syndrome. Genet Med. 2012;14(8):729–36.PubMedPubMedCentralGoogle Scholar
  23. 23.
    Hall DA, Berry-Kravis E, Zhang W, Tassone F, et al. FMR1 gray-zone alleles: association with Parkinson’s disease in women? Mov Disord. 2011;26(10):1900–6.PubMedPubMedCentralGoogle Scholar
  24. 24.
    Loesch D, Tassone F, Lo J, Slater H, et al. New evidence for, and challenges in, linking small CGG repeat expansion FMR1 alleles with Parkinson’s disease. Clin Genet. 2013;84(4):382–5.PubMedPubMedCentralGoogle Scholar
  25. 25.
    Hall D, Tassone F, Klepitskaya O, Leehey M. Fragile X–associated tremor ataxia syndrome in FMR1 gray zone allele carriers. Mov Disord. 2012;27(2):297–301.Google Scholar
  26. 26.
    Liu Y, Winarni T, Zhang L, Tassone F, Hagerman R. Fragile X-associated tremor/ataxia syndrome (FXTAS) in grey zone carriers. Clin Genet. 2013;84(1):74–7.PubMedPubMedCentralGoogle Scholar
  27. 27.
    Bretherick KL, Fluker MR, Robinson WP. FMR1 repeat sizes in the gray zone and high end of the normal range are associated with premature ovarian failure. Hum Genet. 2005;117(4):376–82.PubMedPubMedCentralGoogle Scholar
  28. 28.
    Renda MM, Voigt RG, Babovic-Vuksanovic D, Highsmith WE, Vinson SS, Sadowski CM, Hagerman RJ. Neurodevelopmental disabilities in children with intermediate and premutation range fragile X cytosine-guanine-guanine expansions. J Child Neurol. 2014;29(3):326–30.PubMedPubMedCentralGoogle Scholar
  29. 29.
    Bechara EG, Didiot MC, Melko M, Davidovic L, et al. A novel function for fragile X mental retardation protein in translational activation. PLoS Biol. 2009;7(1):133.Google Scholar
  30. 30.
    Bushey D, Tononi G, Cirelli C. The Drosophila fragile X mental retardation gene regulates sleep need. J Neurosci. 2009;29(7):1948–61.PubMedPubMedCentralGoogle Scholar
  31. 31.
    Bushey D, Tononi G, Cirelli C. Sleep and synaptic homeostasis: structural evidence in Drosophila. Science. 2011;332(6037):1576–81.PubMedPubMedCentralGoogle Scholar
  32. 32.
    van Alphen B, Yap MH, Kirszenblat L, Kottler B, van Swinderen B. A dynamic deep sleep stage in Drosophila. J Neurosci. 2013;33(16):6917–27.PubMedPubMedCentralGoogle Scholar
  33. 33.
    Tirosh E, Borochowitz Z. Sleep apnea in fragile X syndrome. Am J Med Genet. 1992;43(1–2):124–7.PubMedPubMedCentralGoogle Scholar
  34. 34.
    Ferri R, Del Gracco S, Elia M, Musumeci SA, Pettinato S. Heart rate variability and autonomic function during sleep in fragile X syndrome. Am J Med Genet. 1999;83(4):296–7.PubMedPubMedCentralGoogle Scholar
  35. 35.
    Gould EL, Loesch DZ, Martin MJ, Hagerman RJ, Armstrong SM, Huggins RM. Melatonin profiles and sleep characteristics in boys with fragile X syndrome: a preliminary study. Am J Med Genet. 2000;95(4):307–15.PubMedGoogle Scholar
  36. 36.
    Miano S, Bruni O, Elia M, Scifo L, et al. Sleep phenotypes of intellectual disability: a polysomnographic evaluation in subjects with Down syndrome and fragile-X syndrome. Clin Neurophysiol. 2008;119(6):1242–7.PubMedPubMedCentralGoogle Scholar
  37. 37.
    Wirojanan J, Jacquemont S, Diaz R, Bacalman S, Anders TF, Hagerman RJ, Goodlin-Jones BL. The efficacy of melatonin for sleep problems in children with autism, fragile X syndrome, or autism and fragile X syndrome. J Clin Sleep Med. 2009;5(2):145.PubMedPubMedCentralGoogle Scholar
  38. 38.
    Kronk R, Dahl R, Noll R. Caregiver reports of sleep problems on a convenience sample of children with fragile X syndrome. Am J Intellect Dev Disabil. 2009;114(6):383–92.PubMedPubMedCentralGoogle Scholar
  39. 39.
    Kronk R, Bishop EE, Raspa M, Bickel JO, Mandel DA, Bailey DB Jr. Prevalence, nature, and correlates of sleep problems among children with fragile X syndrome based on a large scale parent survey. Sleep. 2010;33(5):679.PubMedPubMedCentralGoogle Scholar
  40. 40.
    Symons FJ, Byiers BJ, Raspa M, Bishop E, Bailey DB Jr. Self-injurious behavior and fragile X syndrome: findings from the national fragile X survey. Am J Intellect Dev Disabil. 2010;115(6):473–81.PubMedPubMedCentralGoogle Scholar
  41. 41.
    Chervin RD, Archbold KH, Panahi P, Pituch KJ. Sleep problems seldom addressed at two general pediatric clinics. Pediatrics. 2001;107(6):1375–80.PubMedPubMedCentralGoogle Scholar
  42. 42.
    Mindell JA, Owens JA. Sleep problems in pediatric practice: clinical issues for the pediatric nurse practitioner. J Pediatr Health Care. 2003;17(6):324–31.PubMedPubMedCentralGoogle Scholar
  43. 43.
    Owens JA. The practice of pediatric sleep medicine: results of a community survey. Pediatrics. 2001;108(3):e51.PubMedGoogle Scholar
  44. 44.
    Lewandowski AS, Toliver-Sokol M, Palermo TM. Evidence-based review of subjective pediatric sleep measures. J Pediatr Psychol. 2011;36(7):780–93.PubMedPubMedCentralGoogle Scholar
  45. 45.
    Kidd SA, Lachiewicz A, Barbouth D, Blitz RK, et al. Fragile X syndrome: a review of associated medical problems. Pediatrics. 2014;134(5):995–1005.PubMedPubMedCentralGoogle Scholar
  46. 46.
    Owens JA, Spirito A, McGuinn M. The Children’s Sleep Habits Questionnaire (CSHQ): psychometric properties of a survey instrument for school-aged children. Sleep. 2000;15(23):1043–51.Google Scholar
  47. 47.
    Goldman SE, Richdale AL, Clemons T, Malow BA. Parental sleep concerns in autism spectrum disorders: variations from childhood to adolescence. J Autism Dev Disord. 2012;42(4):531–8.PubMedPubMedCentralGoogle Scholar
  48. 48.
    Souders MC, Mason TB, Valladares O, Bucan M, et al. Sleep behaviors and sleep quality in children with autism spectrum disorders. Sleep. 2009;32(12):1566.PubMedPubMedCentralGoogle Scholar
  49. 49.
    Gruber R, Fontil L, Bergmame L, Wiebe ST, Amsel R, Frenette S, Carrier J. Contributions of circadian tendencies and behavioral problems to sleep onset problems of children with ADHD. BMC Psychiatry. 2012;12(1):212.PubMedPubMedCentralGoogle Scholar
  50. 50.
    Sciberras E, Fulton M, Efron D, Oberklaid F, Hiscock H. Managing sleep problems in school aged children with ADHD: a pilot randomised controlled trial. Sleep Med. 2011;12(9):932–5.PubMedPubMedCentralGoogle Scholar
  51. 51.
    Lara Ledesma D. A Spanish version of the Children’s Sleep Habits Questionnaire (CSHQ). Electronic Theses, Projects, and Dissertations 2014;Paper 89. http://scholarworks.lib.csusb.edu/etd/89.
  52. 52.
    Liu X, Liu L, Owens JA, Kaplan DL. Sleep patterns and sleep problems among schoolchildren in the United States and China. Pediatrics. 2005;115(Suppl 1):241–9.PubMedPubMedCentralGoogle Scholar
  53. 53.
    Tzchishinsky O, Lufi D, Shochat T. Reliability of the Children’s Sleep Habits Questionnaire Hebrew translation and cross cultural comparison of the psychometric properties. Sleep Diagn Ther. 2008;3:30–4.Google Scholar
  54. 54.
    Sadeh A. Commentary: comparing actigraphy and parental report as measures of children’s sleep. J Pediatr Psychol. 2008;33(4):406–7.PubMedPubMedCentralGoogle Scholar
  55. 55.
    World Health Organization. International classification of functioning, disability, and health: children & youth version: ICF-CY. World Health Organization; 2007.Google Scholar
  56. 56.
    Mindell JA, Owens JA. A clinical guide to pediatric sleep: diagnosis and management of sleep problems. Philadelphia, PA: Lippincott Williams & Wilkins; 2015.Google Scholar
  57. 57.
    Weiskop S, Richdale A, Matthews J. Behavioural treatment to reduce sleep problems in children with autism or fragile X syndrome. Dev Med Child Neurol. 2005;47(02):94–104.PubMedPubMedCentralGoogle Scholar
  58. 58.
    Kulman G, Lissoni P, Rovelli F, Roselli MG, Brivio F, Sequeri P. Evidence of pineal endocrine hypofunction in autistic children. Neuroendocrinol Lett. 2000;21(1):31–4.PubMedPubMedCentralGoogle Scholar
  59. 59.
    Tordjman S, Anderson GM, Pichard N, Charbuy H, Touitou Y. Nocturnal excretion of 6-sulphatoxymelatonin in children and adolescents with autistic disorder. Biol Psychiatry. 2005;57(2):134–8.PubMedPubMedCentralGoogle Scholar
  60. 60.
    Tordjman S, Anderson GM, Bellissant E, Botbol M, et al. Day and nighttime excretion of 6-sulphatoxymelatonin in adolescents and young adults with autistic disorder. Psychoneuroendocrinology. 2012;37(12):1990–7.PubMedGoogle Scholar
  61. 61.
    Bailey DB, Raspa M, Bishop E, Olmstead M, Mallya U, Berry-Kravis E. Medication utilization for targeted symptoms in children and adults with fragile X syndrome: US survey. J Dev Behav Pediatr. 2012;33:62–9.PubMedPubMedCentralGoogle Scholar
  62. 62.
    Angriman M, Caravale B, Novelli L, Ferri R, Bruni O. Sleep in children with neurodevelopmental disabilities. Neuropediatrics. 2015;46(3):199–210.PubMedPubMedCentralGoogle Scholar
  63. 63.
    Hollway JA, Aman MG. Pharmacological treatment of sleep disturbance in developmental disabilities: a review of the literature. Res Dev Disabil. 2011;32(3):939–62.PubMedGoogle Scholar
  64. 64.
    Appleton R, Jones AP, Gamble C, Williamson PR, et al. The use of melatonin in children with neurodevelopmental disorders and impaired sleep: a randomized, double-blind, placebo-controlled, parallel study (MENDS). Health Technol Assess. 2012;16(40):8–239.Google Scholar
  65. 65.
    Hagerman R, Riddle J, Roberts L, Breese K, Fulton M. Survey of the efficacy of clonidine in fragile X syndrome. Dev Brain Dysfunct. 1995;8(4–6):336–44.Google Scholar
  66. 66.
    Ming X, Gordon E, Kang N, Wagner GC. Use of clonidine in children with autism spectrum disorders. Brain Dev. 2008;30(7):454–60.PubMedGoogle Scholar
  67. 67.
    Raspa M, Bailey DB Jr, Bishop E, Holiday D, Olmsted M. Obesity, food selectivity, and physical activity in individuals with fragile X syndrome. Am J Intellect Dev Disabil. 2010;115(6):482–95.PubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Nursing, Duquesne UniversityPittsburghUSA
  2. 2.Fragile X Clinic, Movement Disorders Clinic, Tourette Syndrome Clinic, Division of Child NeurologyChildren’s Hospital of PittsburghPittsburghUSA

Personalised recommendations